Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 11, 2022
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
Tue, May 10, 2022
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $17 on, May 10th, 2022
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $30 to $17 on, May 10th, 2022.
Matthew has made no other calls on ADCT in the last 4 months.
There is 1 other peer that has a rating on ADCT. Out of the 1 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $54 on, Friday, March 4th, 2022
